Repros Therapeutics Inc. (NASDAQ:RPRX) was upgraded by investment analysts at Ladenburg Thalmann from a “neutral” rating to a “buy” rating in a report released on Wednesday.

RPRX has been the topic of a number of other research reports. S&P Equity Research raised their target price on Repros Therapeutics from $2.12 to $2.47 in a report on Thursday, September 8th. Zacks Investment Research raised Repros Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Tuesday, August 16th.

Shares of Repros Therapeutics (NASDAQ:RPRX) opened at 1.88 on Wednesday. The firm’s market capitalization is $45.72 million. The company’s 50 day moving average price is $1.88 and its 200-day moving average price is $1.93. Repros Therapeutics has a 52 week low of $0.80 and a 52 week high of $3.48.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, November 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.01. Repros Therapeutics had a negative return on equity of 151.63% and a negative net margin of 39,128.00%. On average, equities research analysts expect that Repros Therapeutics will post ($0.71) EPS for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Allegis Investment Advisors LLC increased its stake in shares of Repros Therapeutics by 0.3% in the second quarter. Allegis Investment Advisors LLC now owns 342,709 shares of the company’s stock worth $569,000 after buying an additional 1,040 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Repros Therapeutics during the first quarter worth approximately $314,000. Sphera Funds Management LTD. purchased a new position in shares of Repros Therapeutics during the third quarter worth approximately $1,805,000. Northern Trust Corp boosted its position in shares of Repros Therapeutics by 8.0% in the third quarter. Northern Trust Corp now owns 65,138 shares of the company’s stock worth $137,000 after buying an additional 4,833 shares during the last quarter. Finally, General American Investors Co. Inc. boosted its position in shares of Repros Therapeutics by 79.5% in the third quarter. General American Investors Co. Inc. now owns 711,123 shares of the company’s stock worth $1,486,000 after buying an additional 315,000 shares during the last quarter. 24.97% of the stock is currently owned by hedge funds and other institutional investors.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

5 Day Chart for NASDAQ:RPRX

Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.